Abstract The present study examined the impact of the menstrual cycle and oral contraceptive use on performance of high-intensity intermittent running in the heat [31.0 (0.2)°C; 23.1 (0.9)% relative humidity]. Seven normally menstruating women (NM) and eight oral contraceptive (OC) users participated in the study. Two trials were undertaken near the predicted midpoint of the follicular (FT) and luteal (LT) phases of the menstrual cycle and the equivalent days for the OC users. Basal serum progesterone concentrations were higher during the LT for the NM group (893) m, P<0.05]. For the NM, rectal temperature, perceived exertion, estimated SR, serum growth hormone, plasma lactate, ammonia and glucose did not differ between phases of the menstrual cycle. For the OC group, heart rate, perceived exertion, sweat rate, plasma lactate and ammonia did not differ between days 1-14 of OC use and days 15-28. However, rectal temperature was higher (P<0.05) and growth hormone tended to be higher (P=0.05) during days 15-28, while plasma glucose was lower (P<0.05). These results demonstrate that for unacclimatised games players the performance of intermittent, high-intensity shuttle running in the heat is unaffected by menstrual cycle phase but is influenced by OC use.
Introduction
Cyclic variations in deep body temperature during the menstrual cycle may alter thermoregulatory responses, and thus possibly performance, when exercising in the heat. In moderate environmental conditions the performance of continuous (90% _ V V O 2max ) and progressive high-intensity running was unaffected by menstrual cycle phase (Lebrun et al. 1995; Lynch and Nimmo 1998) . However, very few studies (Carpenter and Nunneley 1988; Horvath and Drinkwater 1982; Stephenson and Kolka 1988) have examined performance in the follicular and luteal phases of the menstrual cycle in the heat, despite numerous international competitions being organised in hot climates. From the studies that have been undertaken it was concluded that cycling and walking performance were unaffected by menstrual phase. In addition, it has been shown that during sub-maximal cycling in the heat for acclimatised subjects, deep body temperature may be higher during the luteal compared with the follicular phase (Carpenter and Nunneley 1988) . For unacclimatised subjects reports are controversial, with deep body temperature reported to be higher (Stephenson and Kolka 1988) or unaffected by menstrual phase (Horvath and Drinkwater 1982; Wells and Horvath 1974) .
Furthermore, no study has examined the metabolic and hormonal responses to exercise in the heat during the follicular and luteal phases of the cycle. In moderate environmental conditions, for sub-maximal cycling and treadmill running, blood glucose was similar in the follicular and luteal phases (Bonen et al. 1983 ; Kanaleyintensity cycling and running, blood glucose has been shown to be lower (Lavoie et al. 1987) or higher during the luteal phase (Galliven et al. 1997; Zderic et al. 2001) . Again in moderate environmental conditions, growth hormone responses to cycling and treadmill walking were higher during the luteal and ovulatory phases of the cycle compared with the follicular phase (Bonen et al. 1983; Hornum et al. 1997; Zderic et al. 2001) . High growth hormone concentrations have been associated with the high oestrogen concentrations during the luteal and ovulatory phases (Hornum et al. 1997) .
Many women mask their normal cyclical hormonal changes during the menstrual cycle by taking oral contraceptives. However, only two research groups have investigated the responses of oral contraceptive users to exercise in the heat (Martin and Buono 1997; Stachenfeld et al. 2000) . During prolonged moderate cycling when taking oral contraceptives, there was a higher heart rate and rectal temperature response compared with the same exercise during a contraceptive-free week (Martin and Buono 1997) . Furthermore, again during cycling, when women were taking a progestin-only contraceptive, oesophageal temperature and sweating threshold were higher than when the women were taking a combined oestrogen and progestin contraceptive (Stachenfeld et al. 2000) . In moderate environmental conditions during moderate and high-intensity treadmill exercise, oral contraceptive users had higher growth hormone and lower glucose concentrations than eumenorrhoeic women (Bemben et al. 1992; Bonen et al. 1991) . However, no study has examined the performance of oral contraceptive users throughout the substitutive therapy cycle in moderate or hot environmental conditions.
A high deep body temperature has been suggested to be a limiting factor in exercise performance in the heat (Gonzalez-Alonso et al. 1999; Nielsen et al. 1990 Nielsen et al. , 1993 . If during the luteal phase or taking oral contraceptives, a higher deep body temperature is observed during exercise, this may decrease the time to exhaustion. Therefore, the purpose of the present study was to test the hypothesis that the performance of high-intensity, intermittent running exercise in the heat is unaffected during the menstrual cycle, or by the use of oral contraceptives. In addition, the responses of the eumennorrhoeic women during the normal menstrual cycle were compared with those of monophasic oral contraceptive users, across a substitutive cycle, before day 14 and after day 14, since the performance, hormonal and metabolic responses have not been studied to date.
Methods

Participants
Fifteen well-trained female games players volunteered for the study, seven of whom had normal menstrual cycles (NM) lasting between 24 and 30 days, and eight who had been taking monophasic oral contraceptives (OC) for a mean (SEM) of 22 (6) months. The mean (SEM) age, mass and height of the NM and OC groups were 20.3 (0.3) years and 20.2 (0.4) years, 62.1 (2.3) kg and 59.8 (1.1) kg and 168.4 (2.0) cm and 165.6 (1.9) cm respectively. The estimated mean (SEM) _ V V O 2max for the NM group was 51.1 (0.7) ml kg -1 min -1 and for the OC group was 50.3 (1.6) ml kg -1 min -1 . All subjects gave their written informed consent and the Loughborough University Ethical Committee approved the study. The oral contraceptives taken by the participants in the OC group are described in Table 1 .
Terminology
The group with normal menstrual cycles will be referred to as NM and the oral contraceptive users as OC. For the NM group the follicular trial will be abbreviated to FT and the luteal trial to LT. Monophasic OC users do not have follicular and luteal phases per se; thus the first 14 days of the OC cycle will be termed days 1-14 and the second 14 day period as days 15-28 of OC use.
Experimental design
Subjects performed the Loughborough Intermittent Shuttle Test (LIST; Nicholas et al. 1995 Nicholas et al. , 2000 in hot environmental conditions [31.0 (0.2)°C, 23.1 (0.9)% RH]. The mean difference ±95% limits of agreement for the LIST is -0.7±5.6 min. For the NM, two main trials were completed during the follicular phase, $7 days after the onset of menstruation and in the luteal phase, $day 21. For OC users, two trials were completed at the equivalent days. The order of trials was randomly assigned and 14 days elapsed between the FT and LT for the NM women and between trials for the OC users. Subjects exercised over a 20 m distance and repeated a walk, sprint, cruise ($95% _ V V O 2max ) and jog ($55% _ V V O 2max ) pattern of exercise until 11 sprints had been completed. The 11 sprints took approximately 15 min and were followed by a 3 min rest period. This series of activities constituted one set of the LIST. This pattern was repeated until exhaustion, or rectal temperature reached 39.5°C.
Preliminary measurements
Maximal oxygen uptake ( _ V V O 2max ) was estimated using the progressive multistage fitness test (Ramsbottom et al. 1988) . From this estimate of _ V V O 2max , running speeds to elicit 95% and 55% _ V V O 2max were determined. Volunteers were then familiarised with the LIST at $30°C for two sets or $30 min.
Main trials
Subjects reported to the laboratory at least 12 h after their last meal. In the 2 days prior to each trial subjects were encouraged to consume the same diet. All experiments were arranged so that each individual ran at the same time of day for both trials to control for circadian influences. Nude body mass was recorded and a 45 mm cannula was then inserted into a forearm vein of the subject under local anaesthetic (lignocaine hydrochloride 1% w/v). The cannula was kept patent with saline solution (sodium chloride 0.9% w/v). A rectal probe (Edale Instruments Ltd.) was inserted to a depth of 10 cm beyond the anal sphincter. Fifteen minutes after cannulation, during which time subjects remained standing, a resting blood sample was collected. Subjects then moved into the gymnasium and a resting rectal temperature was recorded. A standardised warm-up of $15 min was performed which consisted of jogging, stretching and faster pace running. During the warm-up and throughout the exercise period subjects were encouraged to drink water to ensure adequate hydration levels.
During the sprints subjects were verbally encouraged to perform maximally. Sprint times over 15 m were measured using two infrared photoelectric cells connected to the microcomputer. Heart rate was continuously monitored throughout each test using short range telemetry (Sport Tester, Polar Electro Fitness Technology). Rating of perceived exertion (RPE) was recorded prior to the 11th sprint in each exercise set using the Borg scale (1962). A 10 ml blood sample was collected from each subject between the sets of exercise and at exhaustion. Rectal temperatures were measured during the fourth and eighth cycle of each set and in the 3 min blood sampling period between sets of LIST. When rectal temperatures were measured subjects were stationary for 40 m of the 60 m walk in that cycle.
At exhaustion, after the participant had stopped sweating and wiped any excess sweat off the skin, nude body mass was again recorded. Sweat rates were estimated from pre-and post-exercise nude body mass measurements correcting for fluid intake. It was assumed that 1 l of water was equivalent to 1 kg.
Blood sampling and analyses
Five millilitres of blood were dispensed into a tube containing EDTA and aliquots from the venous sample were used for determination of haematocrit (by microcentrifugation) and haemoglobin concentration by the cyanmethaemoglobin method (Boehringer Mannheim). Changes in plasma volume (%) were estimated using the method of Dill and Costill (1974) . One millilitre of blood was dispensed immediately into a calcium-heparin tube, centrifuged for 3 min at 11,337 g and the plasma was frozen at -70°C. Ammonia concentration was determined within 24 h using a commercially available kit (Sigma Diagnostics). The remaining blood was centrifuged for 15 min at 2415 g at $3°C. The resulting plasma was then stored at -20°C for subsequent determination of lactate and glucose concentrations using fully automated colorimetric instrumentation (Cobas Mira, Roche).
Five millilitres of blood were also dispensed into a serum tube for determination of progesterone and growth hormone concentrations by using commercially available radioimmunoassay kits (Diagnostic Products). The progesterone assay has a sensitivity of 0.06 nmol l -1 , an intra-assay coefficient of variation (CV) of 2.7-8.8% and an inter-assay CV of 3.9-9.7%. The growth hormone assay has a sensitivity of 1.8 mIU l -1 , an intra-assay CV of 1.5-5.9% and an inter-assay CV of 3.4-8.3%.
Statistical analyses
Statistical analyses were undertaken on the NM and OC groups independently to allow comparisons between trials. The physiological and blood responses to the performance of the LIST were analysed using a two-way analysis of variance (ANOVA; trial·time) with repeated measures on one factor (time). Significant differences between means were identified using a Tukey post hoc test. Environmental temperatures, distance covered during the LIST, body mass and plasma volume responses during the main trials were analysed using a Student's t-test. Comparisons between groups and trials were also undertaken. The physiological and blood responses to the performance of the LIST were analysed using a three-way analysis of variance (ANOVA; group·trial·time) with repeated measures on two factors (trial·time). Environmental temperatures, distance covered during the LIST, body mass and plasma volume responses during the main trials were analysed using a two-way ANOVA (group·trial) with repeated measures on one factor (trial). Significant differences between means were identified using a Scheffe´post hoc test. Data are presented as means (SEM) and are based on a subject population of seven NM and eight OC unless otherwise stated.
Results
Performance
The distance run during the LIST was not different between groups, all cycles considered [NM: 6059 (896) m vs OC: 6048 (543) Maximal 15-m sprint performance did not differ between groups and the decline in performance was similar both between groups and between trials (main effect time P<0.01, Fig. 1 ).
Rectal temperature
The resting rectal temperatures tended to be higher prior to the LT than the FT, [Rest, FT: 37.1 (0.1)°C vs LT: 37.2 (0.1)°C, n.s., Table 2 Resting rectal temperature was higher for the OC than the NM being 37.4 (0.1)°C and 37.2 (0.1)°C respectively (P<0.05). The difference observed at rest between the OC and NM was not maintained after the onset of exercise. The rate of rise of rectal temperature showed no differences between the two groups [NM: 3.4 (0.4)°C h -1 vs 2.6 (0.2)°C h -1 ].
Heart rate and RPE Heart rate increased with exercise time for both the NM and OC groups (main effect time P<0.01). Heart rate was unaltered by menstrual phase or OC status and did not differ between the groups. Tables 4 and 5 show that RPE increased with exercise time (P<0.01) and was not different between menstrual phase or OC use.
Body mass, fluid consumption and estimated sweat rate Body mass was well maintained by both groups during the two trials. The change in body mass as a percentage of basal body mass for the NM was -0.13 (0.24)% and 0.06 (0.16)% for the FT and LT respectively and for the OC it was -0.51 (0.10)% and -0. ] confirming the inhibition of ovulation. Serum growth hormone concentrations for the NM increased with the onset of running and were not different between menstrual cycle phases [main effect time P<0.05; Table 6 ], but tended to be higher for the OC during days 15-28 [main effect trial P=0.05, main effect time P<0.01; Table 7 ]. However, the concentrations were not different between the groups.
Metabolic responses
For the NM both plasma lactate and ammonia responses did not differ between menstrual cycle phases (main effect time P<0.01, Table 8 ). Similarly for the OC plasma lactate and ammonia did not differ between days 1-14 and 15-28 (main effect time P<0.01, Table  8 ). For the NM plasma glucose concentrations were unaffected by menstrual phase [NM FT End: 9.6 (1.2) mmol l -1 vs LT End 8.3 (0.9) mmol l -1 ; main effect time P<0.01]. For the OC, plasma glucose concentration was higher during days 1-14 than days 15-28 (main effect trial P<0.05, main effect time P<0.01; Fig. 2 ).
Plasma volume
Estimated resting plasma volume was not different between the FT and LT for the NM [FT: 62.2 (1.1) ml (100 ml) -1 vs LT: 61.9 (1.3) ml (100 ml) -1 ]. However resting plasma volume for the OC was higher during the days 15-28 than 1-14, [1-14: 61.0 (1.1) ml (100 ml) -1 vs 15-28: 63.4 (1.3) ml (100 ml) -1 ; P<0.05]. There were no differences in resting plasma volume between the groups. The estimated change in plasma volume for the NM and OC groups was not different between trials. The decreases in plasma volume were not different between the two groups. 
Discussion
The main finding in the present study was that in unacclimatised women, who were eumenorrhoeic, performance, in terms of distance run of prolonged intermittent high-intensity running, was not significantly affected by the cyclic variations in hormones associated with normal menstrual function, whereas for OC users performance was improved during days 15-28 when taking exogenous synthetic hormones compared to days 1-14. For the eumenorrhoeic group maximal sprint performance over 15 m, rectal temperature, plasma lactate, ammonia and glucose concentrations and serum growth hormone concentrations were also not different between the follicular and luteal phases of the menstrual cycle. However, for the OC users plasma glucose concentration was higher and serum growth hormone concentrations were lower in days 1-14 in comparison with days 15-28.
The finding of the present study that the performance, rectal temperature, heart rate and perceived exertion of unacclimatised eumenorrhoeic women during intermittent running in the heat [31 (0.2)°C; 23.1(0.9)% RH] were unaffected by menstrual cycle phase is largely consistent with previous research examining other modes of exercise Drinkwater 1982, Wells and Horvath 1974) . During walking in three different environments (28°C, 35°C and 48°C) during the flow (follicular), ovulatory and luteal phases no differences in heart rate, deep body temperature, sweat rate or performance of the 50-min walk were observed between the three phases (Horvath and Drinkwater 1982) . In contrast in acclimatised eumenorrhoeic subjects cycling (30% _ V V O 2max ) in the heat (48°C, 10% RH), rectal temperature was lower in the follicular in comparison with the luteal phase (Carpenter and Nunneley 1988) in good agreement with the well-documented effect of progesterone on basal body temperature. Similarly during cycling at night (70% _ V V O 2max ) (when the largest differences in deep body temperature between the luteal and follicular phase are observed) in moderate environmental conditions after a 4 h rest period in the heat, rectal temperature, heart rate, sweating thresholds and oxygen uptake were all lower during the follicular in comparison with the luteal phase (Hessemer and Bru¨ck 1985) . Thus, in the present study, while the similar running performance in the follicular and luteal phases of the cycle is entirely consistent with previous cycling and walking studies, the lack of any effect on deep body temperature or cardiovascular responses may be explained by the unacclimatised status of the subjects and the intense nature of the exercise.
One exception to the consistency with previous literature in the present study is the lack of any difference in rectal temperature between menstrual phases for the eumenorrhoeic women prior to the onset of exercise. This may possibly be due to the intervening variables associated with travelling to the laboratory and the long preparation period (Wells and Horvath 1973) . The similar basal deep body temperatures between menstrual phases emphasises the need for a prolonged period of passive rest prior to the onset of exercise, to prevent the masking of the differences in deep body temperature associated with the follicular and luteal phases of the cycle.
For the OC users, performance was improved during days 15-28 compared to days 1-14. No previous study has examined performance per se during exercise in the heat in OC users. However, during cycling for 1 h at 60% _ V V O 2max in the heat (30°C, 50% RH) rectal temperature and heart rate were greater when subjects were taking OC in comparison with a contraceptive-free week, which the authors suggested might result in reduced capacity or performance in OC users (Martin and Buono 1997) . Similarly, Rogers and Baker (1997) recorded a higher rectal temperature and heart rate when subjects were taking the contraceptive pill compared with the no-pill week during treadmill walking (22°C, 39% RH). In the current study rectal temperature was 0.1°C higher during days 15-28, whereas in the studies comparing pill-use with the pill-free week temperatures were 0.3°C higher (Martin and Buono 1997; Rogers and Baker 1997) . Martin and Buono (1997) postulated that the high rectal temperature may diminish performance; however in the current study performance was actually improved. The difference of only 0.1°C clearly therefore did not have a negative effect on performance.
There was a higher plasma glucose concentration during the high-intensity intermittent running during days 1-14 in comparison with days 15-28 in the present study, for the OC group. Previous studies examining glucose concentration and OC use have yielded equivocal findings with increases, decreases and no change in glucose concentrations being recorded (Bailey et al. 2000; Bemben 1993; Bonen et al. 1991; Galliven et al. 1997; Kanaley et al. 1992) . These ambivalent findings might be related to the intensity and type of exercise, the type of OC, the time during the contraceptive month and whether the subjects are fasted. When the metabolic contribution required from gluconeogenesis is high there tends to be a higher glucose concentration for OC users during the contraceptive-free week or when compared to eumenorrhoeic women (Bemben 1993; Bonen et al. 1991; Lavoie et al. 1987) . During prolonged exercise, blood glucose is initially supplied from the breakdown of glycogen and as exercise progresses gluconeogenesis becomes more crucial. In the current study, the differences in glucose concentrations became greater towards the end of the exercise period. Thus, the lower glucose concentration during days 15-28 may be related to the higher exogenous ovarian hormones that may impair hepatic gluconeogenesis (Lavoie et al. 1987) . The lower glucose response could also be due to a decrease in hepatic glucose output or an enhanced glucose uptake, utilisation and glycogen storage that has been shown with oestrogen treatment in animals (Bemben 1993) . Furthermore, OC have been suggested to alter the secretion of glucoregulatory hormones and to decrease insulin sensitivity that suppresses gluconeogenesis as insulin concentrations have been shown not to differ (Bemben 1993; Bonen et al. 1991) .
Growth hormone was higher during second 14 day period for the OC users. Growth hormone has been reported to be higher both at rest and during exercise when taking oral contraceptives compared to the contraceptive-free week and to eumenorrhoeic women (Bemben 1993; Bemben et al. 1992; Bonen et al.1991) . This enhanced growth hormone response may be due to oestrogen stimulation or could be due to the lower glucose concentrations stimulating hypothalamic glucoreceptors (Bemben et al. 1992 ). Growth hormone is associated with an enhanced lipolytic effect and thus has a glucose sparing effect (Bak et al. 1991; Moller et al. 1991) , which may improve performance during prolonged exercise (Bemben 1993; Bemben et al. 1992) . Total carbohydrate utilisation during 90 min of treadmill exercise (50% _ V V O 2max ) was lower in women taking OC than women in the luteal phase of the cycle and this was suggested to be related to the higher growth hormone response in this group (Bemben et al. 1992) . Thus in the present study the improved performance may be related to a glycogen sparing effect; however as free fatty acids, insulin and glucagon were not measured, this clearly requires further study.
A possible explanation for the improved performance during days 15-28 for the OC users is an enhanced running economy. Giacomoni and Falgairette (2000) compared responses to a 12-min submaximal treadmill run when off OC (days 2-4), early on OC use (days 7-9) and late on OC use (days 19-21). Oxygen uptake was lower during early and late OC use compared to off OC and running economy was improved in late OC use compared to off OC. It was postulated that this may be related to biomechanical factors rather than any alteration in substrate utilisation. Furthermore, Lynch and Nimmo (1998) observed higher blood lactate and ammonia responses to high-intensity intermittent running within 1 week of taking the OC compared to 1 week later. Though this did not impact upon performance, it clearly emphasises the differences in metabolism that may occur within one contraceptive cycle.
The only difference between the groups was a higher resting rectal temperature in the OC group than in the eumenorrhoeic group. The progestin concentration in the OC was high (>150 lg) and therefore the increase in basal body temperature, in line with progestin concentration, was not of a gradual nature as seen in the menstrual cycle, where progesterone is only produced during the luteal phase of the cycle, or in multiphasic OC preparations, where progestins are only added during the second 14 days (second phase) of the cycle. Furthermore the potency of exogenous progestins has been shown to be greater than their endogenous counterparts (Bemben 1993) . Thus exogenous progestins have a significant effect upon thermoregulation (Grucza et al. 1993; Rogers and Baker 1997) . Both the high progestin concentration and potency of the OC seem the likely explanation for the higher resting rectal temperatures observed.
The protocol employed in the present study was designed to allow comparison between groups primarily and as such the lack of specificity of the OC cycle is a major limitation. For example, some of the participants would have been taking OC for 1-2 days after the week off during the days 1-14 trial. This time has previously been associated with a feeling of nausea and may have diminished performance. However, taking account of the limitations in protocol design, there are clearly some important differences in terms of performance, and some possible mechanisms for these differences that require further investigation. Research needs to be undertaken during several specific time periods during the OC month, which incorporates measurement of growth hormone, glucoregulatory hormones, glucose and free fatty acids.
In summary, menstrual cycle phase did not affect performance in terms of distance run or 15 m maximal sprint time during prolonged intermittent high-intensity shuttle running in the heat. However, performance was improved during days 15-28 compared to days 1-14 of the contraceptive month. This improvement in performance may be related to a glycogen sparing effect or a biomechanical improvement though this remains to be elucidated.
